LIlly comes on board at think tank

Share this article:
Eli Lilly
Eli Lilly

National Pharmaceutical Council (NPC) said Eli Lilly joined earlier this year. NPC conducts research on topics like the challenges of individual patient treatment effects, utilization of real-world evidence and comparative effectiveness research.

In a statement, Mark Nagy, Lilly VP, global patient outcomes and real world evidence, said, “With the full implementation of the Affordable Care Act, access to healthcare and medicines is becoming a reality for more Americans, while at the same time the personalization of drug treatments is beginning to become a reality. These changes are sparking new conversations and challenges, and I look forward to working with NPC to address them.”

Nagy will serve as Lilly's representative on the NPC board of directors.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Headliner: Ipsen head leads continental charge

Headliner: Ipsen head leads continental charge

"When I look at the business, I actually see patients in my mind. I don't see numbers."

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets